Poseida Therapeutics is letting go of 52 employees from its San Diego location, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The layoffs will take effect Oct. 1. It is unclear if the workforce reduction is in connection with the Roche acquisition.
All entries for: Layoffs
August 8, 2025
Poseida Therapeutics
Layoffs
San Diego, CA
201-500 employees
Disease Area: Hematology, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
August 8, 2025
Precision BioSciences
Layoffs
Durham, NC
51-200 employees
Delaware-based Precision BioSciences has terminated an undisclosed number of employees in order to extend its cash runway into the second half of 2027.
Disease Area: Chronic Disease, Hematology, Infectious Diseases, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
August 8, 2025
Iovance Biotherapeutics
Layoffs
San Carlos, CA
501-1,000 employees
Months after lowering its full-year guidance, Iovance Biotherapeutics has slashed its headcount by fewer than 20%, according to an Aug. 6 report from Endpoints News, which confirmed the layoffs with a company spokesperson. “This restructuring will extend our cash runway,” the spokesperson told Endpoints, adding that the layoffs will “support [its] mission to innovate, develop and deliver” its pipeline of tumor-infiltrating lymphocyte cell therapies for patients who need them.
Disease Area: Oncology
Drug Type: Biologic
August 7, 2025
Bayer
Layoffs
Whippany, NJ
50,001+ employees
Workforce cuts continue at Bayer, with CEO Bill Anderson announcing on the company’s second-quarter earnings call on Aug. 6 that it expects more layoffs to come. These would follow the 2,000 employees it said it was letting go during first-quarter earnings and around 11,000 total since Bayer initiated a sweeping reorganization initiative in July 2023.
Disease Area: Cardiology, Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule
August 7, 2025
BioNTech
Layoffs
Gaithersburg, MD
5,001-10,000 employees
BioNTech is laying off 90 employees across its U.S. footprint as the company plots its future in a post-COVID market.
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
August 4, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 1, 2025
Moderna
Layoffs
Cambridge, MA
1,001-5,000 employees
Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company,” CEO Stéphane Bancel told employees in a note July 31.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
July 30, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 29, 2025
Adaptimmune Therapeutics
Layoffs
Oxfordshire, UK
201-500 employees
U.K.-based Adaptimmune Therapeutics plans to cut 62% of its workforce once its deal to sell four cell therapy assets to US WorldMeds closes, according to an SEC filing. US WorldMeds, a specialty pharma based in Louisville, Kentucky, intends to offer employment to about half of the biotech’s workforce as part of the transaction, the filing noted.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
July 28, 2025
Rocket Pharmaceuticals
Layoffs
Cranbury, NJ
201-500 employees
Rocket Pharmaceuticals is laying off 30% of its workforce in a strategic realignment initiative that also involves focusing resources on its late-stage heart disease programs, the company announced July 24. A total of 80 employees at Rocket’s Cranbury, New Jersey, site will be affected, according to a Workers Adjustment and Retraining Notification (WARN) Act notice. The layoffs will start Oct. 23 and continue through the end of the year, as per the WARN posting, and will allow Rocket to reduce its 12-month cash burn by almost 25%.
Disease Area: Cardiology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Biologic